Synapse - Works

Results (69)

KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced solid tumors harboring a KRAS(G12C) mutation

Meeting Abstract

Pant, S.; Yaeger, R.; Spira, A. I.; Pelster, M.; Sabari, J. K.; Hafez, N.; Barve, M. A.; Velastegui, K.; Yan, X. H.; Der-Torossian, H.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

A randomized trial of consolidation-targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II/III BRAF V600E colon cancer: Alliance for Clinical Trials in Oncology A022004

Meeting Abstract

Yaeger, R.; Shi, Q.; Dueck, A. C.; Dib, E. G.; Kazmi, S. M. A.; Alese, O. B.; Krishnamurthi, S. S.; Nixon, A. B.; Shergill, A.; O'Reilly, E. M.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations

Meeting Abstract

Beck, J. T. T.; McKean, M.; Gadgeel, S. M.; Bowles, D. W.; Haq, R.; Yaeger, R.; Taylor, M. H.; Maity, A. K.; Drescher, S.; Oliver, C.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC)

Meeting Abstract

Kopetz, S.; Yoshino, T.; Kim, T. W.; Wasan, H. S.; Van Cutsem, E.; Ciardiello, F.; Maughan, T. S.; Eng, C.; Yaeger, R.; Desai, J.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Negative selection of patients (pts) with HER2-positive and RAS wild-type (wt) metastatic colorectal cancer (mCRC) receiving dual HER2 blockade

Meeting Abstract

Randon, G.; Nakamura, Y.; Yaeger, R.; Lonardi, S.; Cremolini, C.; Elez, E.; Nichetti, F.; Ghelardi, F.; Nasca, V.; Bergamo, F.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Effect of somatic-germline genomic integration on the contribution of pathogenic germline genetic variants (gPV) to colorectal cancer (CRC) carcinogenesis

Meeting Abstract

Harrold, E.; Walch, H. S.; Chatila, W. K.; Kemel, Y.; Borio, M.; Maio, A.; Khurram, A.; Salo-Mullen, E. E.; Latham, A.; Murciano-Goroff, Y. R.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Circulating tumor DNA (ctDNA) to assess response in patients with anal cancer treated with definitive chemoradiation

Meeting Abstract

Alvarez, J.; Cercek, A.; Mohan, N.; Ho, Y. J.; Zinovoy, M.; Reyngold, M.; Yaeger, R.; Hajj, C.; Fanta, C.; Roth O'Brien, D. A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Tumor-agnostic genomic and clinical analysis of solid tumors with BRAF fusions

Meeting Abstract

Chen, M. F.; Yang, S. R.; Tao, J.; Desilets, A.; Rosen, E.; Gong, Y.; Mullaney, K. A.; Kris, M. G.; Arcila, M. E.; Donoghue, M.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Dose optimization of novel BRAF inhibitor FORE8394 based on PK and efficacy results

Meeting Abstract

Sherman, E. J.; De La Fuente, M. I.; Yaeger, R.; Tsai, F. Y.C.; Janku, F.; Butowski, N. A.; Allen, C. E.; Ammakkanavar, N. R.; Taylor, J. W.; Samara, E.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers

Meeting Abstract

Liu, D.; Makker, V.; Buonocore, D. J.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Johnson, A.; Offin, M.; Solit, D. B.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save